# How Haleon (HLN) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/hln
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on HLN alone. It places HLN (Haleon plc) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where HLN stands in the market, and of the alternatives worth a closer look.

Period covered: HLN's full trading record, from July 2022 through September 2026. The crash tests reach back to 2000 using older funds and the S&P 500. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** HLN has bounced back 17.6% from its June 2026 low after a 23.2% loss from June 2025 to June 2026 over the same months the S&P 500 rose 29.6%. Its consumer health peers split over the past 6 months: EL (Estée Lauder Companies) rose 37.3%, while HLF (Herbalife Nutrition) fell 18.9%.
- **Stock or market?:** HLN lagged its own industry over the past 3 months, rising 1.9% while the consumer health ETF XLV (State Street Health Care Select Sector SPDR ETF) rose 13.4%. The S&P 500 rose 3.9%. Its consumer health peers did not move as one over the past 3 months: EL (Estée Lauder Companies) rose 27.3%, while USNA (USANA Health Sciences) fell 34.3%.
- **Past 1 to 3 years:** Over the past year, HLN rose 8.8% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (28.9% against 89.3%). The last two calendar years both went the same way: HLN rose 7.8% in 2025, against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100.
- **Long term:** HLN turned $10,000 into $12,900 over the past 3 years, against $18,900 in the S&P 500. That said, over the past 3 years, only CL (Colgate-Palmolive) of its consumer health peers outpaced HLN.
- **Diversification:** Over 3 years, HLN's beta versus the S&P 500 was 0.04: 33% of the S&P 500's gains in rising months and 68% of its losses in falling ones. On the flip side, against the S&P 500, HLN has a correlation of 0.02 over 3 years, less closely than 93% of stocks worth at least $300 million. Next to an index fund it is a real diversifier.
- **Better options**
  - **Nearby categories and themes:** JNJ (Johnson & Johnson, pharmaceuticals) and COST (Costco Wholesale, discount retail) earned more than HLN with less volatility over the past 3 years. JNJ returned 22.7% a year at 18.4% volatility, against 8.8% a year at 21.5%.
  - **Whole market:** 755 of the 3,928 stocks and funds worth at least $500 million earned more than HLN with less volatility over the past 3 years, among them VTI (Vanguard Morningstar Total Stock Market ETF), VOO (Vanguard S&P 500 ETF) and BRK-B (Berkshire Hathaway).

## How much would $10,000 in HLN have grown?

This chart tracks a hypothetical $10,000 investment in HLN over the past 4 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of HLN over the same span and HLN's popular alternatives, among those that traded for the entire period.

- $10,000 invested in HLN at the end of September 2022 would have grown to $15,598 by September 2026, less than the $22,487 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of HLN, and ELF finished highest, at $26,841.

## HLN at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- HLN has not had a losing calendar year since it began trading in 2022; it gained in all three full years, at worst 4.1% in 2023.
- HLN's deepest decline since it began trading in 2022 was 24.9%, from July to September 2022. It took three months from the low to climb back to its old high.
- HLN is 9.8% below its all-time high.

- Type: Stock, Healthcare (Drug Manufacturers - Specialty & Generic)
- Trading since: July 18, 2022
- Market value: $45B
- Volatility (3 years): 21.5%; Sharpe ratio: 0.50
- Worst decline ever: −24.9%, from July 18, 2022 to September 2, 2022; back at its high by December 6, 2022

| Period | HLN total return |
| --- | --- |
| 1 month | +8.7% |
| 3 months | +1.9% |
| 6 months | +5.7% |
| year to date | +2.3% |
| 1 year | +8.8% |
| 3 years | +28.9% |

## HLN against the whole market

Where HLN ranks among every stock and fund, and what across the market has done better.

### How does HLN rank among all stocks?

This section ranks HLN on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- HLN is among the steadier stocks: its price swings rank in the top 7% of the 3,017 stocks worth at least $300 million, where the top is the calmest.

| Measure | HLN | Rank |
| --- | --- | --- |
| 1-year return | +8.8% | 1,628 of 3,287 (top 50%) |
| 3-year return | +28.9% | 1,865 of 3,017 (top 62%) |
| Volatility, 3 years | 21.5% | 213 of 3,017 (top 8%) |
| Sharpe ratio, 3 years | 0.50 | 1,773 of 3,017 (top 59%) |

### What has beaten HLN on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 3 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- 86 stocks and 669 ETFs worth at least $500 million sit in the green region: each earned more than HLN over the past 3 years with smaller price swings. That is 19% of the 3,928 screened.
- Among those with at least half HLN's swings, WCCB has the best return for its risk: 37.6% a year at 13.8% volatility, 36% less than HLN's 21.5%, and a Sharpe ratio (return above cash per unit of volatility) of 2.39 against 0.50 for HLN. CM earned the most, 53.4% a year, while still swinging less than HLN (19.8% against 21.5%).
- Among HLN's popular alternatives, CL is in the region. CL earned 11.4% a year against 8.8% a year for HLN, at 19.8% volatility, 8% less than HLN's 21.5%.

### Is there a better investment than HLN?

The table below lists investments that beat HLN over the past 3 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Among HLN's popular alternatives, CL earned more than HLN with less volatility over the past 3 years: 11.4% a year at 19.8% volatility, against 8.8% a year at 21.5%.
- Looking beyond its popular alternatives, JNJ (pharmaceuticals) and COST (discount retail) earned more than HLN with less volatility over the past 3 years. JNJ returned 22.7% a year at 18.4% volatility, against 8.8% a year at 21.5%.
- Across the whole market, 755 of the 3,928 stocks and funds worth at least $500 million earned more than HLN with less volatility over the past 3 years, among them VTI, VOO and BRK-B.

The 15 strongest of 755 investments that beat HLN over the past 3 years, out of 3,928 stocks and funds worth at least $500 million.

| Investment | Group | Annual return (3 years) | Volatility | Sharpe | Worst decline (10 years) | 3Y return | Correlation with HLN | Better on |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| HLN: Haleon plc (this page) |  | +8.8% | 21.5% | 0.50 | −24.9% | +28.9% |  |  |
| BUFR: FT Vest Laddered Buffer ETF | Buffered Equity | +15.9% | 8.6% | 1.77 | −13.7% | +55.8% | 0.07 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| CLSE: Convergence Long/Short Equity ETF | Broad Market | +29.1% | 13.8% | 1.93 | −16.4% | +115% | -0.14 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| PSEP: Innovator U.S. Equity Power Buffer ETF | Broad Market | +13.6% | 7.3% | 1.80 | −17.9% | +46.5% | 0.08 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| BUFZ: FT Vest Laddered Moderate Buffer ETF | Multi-Asset | +13.5% | 7.0% | 1.86 | −10.1% | +46.3% |  | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| XEMD: BondBloxx JP Morgan USD Emerging Markets 1-10 Year Bond ETF | Bonds | +10.7% | 5.5% | 1.90 | −10.0% | +35.8% | 0.39 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [RY](https://easycompare.io/research/ry): Royal Bank of Canada | Banks | +39.7% | 16.9% | 2.08 | −40.0% | +173% | 0.26 | Higher return, lower volatility |
| [JEPI](https://easycompare.io/research/jepi): JPMorgan Equity Premium Income ETF | Equity Income | +11.4% | 10.0% | 1.14 | −13.7% | +38.1% | 0.43 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| AVLV: Avantis U.S. Large Cap Value ETF | US Large-Cap Value | +23.7% | 14.8% | 1.52 | −19.5% | +89.4% | 0.19 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| VFLO: VictoryShares Free Cash Flow ETF | US Large-Cap Value | +30.8% | 16.4% | 1.73 | −17.8% | +124% | 0.27 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| DFUV: Dimensional - US Marketwide Value ETF | US Value Equity | +21.7% | 14.3% | 1.46 | −17.6% | +80.3% | 0.23 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| [CM](https://easycompare.io/research/cm): Canadian Imperial Bank of Commerce | Banks | +53.4% | 19.8% | 2.27 | −47.3% | +261% | 0.24 | Higher return, lower volatility |
| SPYI: Neos S&P 500(R) High Income ETF | Equity Income | +18.3% | 12.5% | 1.42 | −16.5% | +65.7% | 0.07 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| TCAF: T. Rowe Capital Appreciation Equity ETF | US Large-Cap Equity | +21.4% | 14.0% | 1.47 | −16.4% | +78.8% | 0.01 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| CGBL: Capital Group Core Balanced ETF | Balanced Allocation | +16.7% | 10.9% | 1.47 | −11.7% | +58.8% | 0.14 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |
| JIVE: JPMorgan International Value ETF | International | +29.0% | 14.9% | 1.80 | −13.8% | +115% | 0.47 | Higher return, lower volatility; Higher Sharpe, smaller worst decline |

## HLN against its popular alternatives

The investments people most often weigh against HLN, compared period by period and year by year.

### How do HLN's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 3 years against its volatility, the size of its typical price swings.

- Only CL was both more rewarding and calmer than HLN over the past 3 years, earning a higher annual return with lower volatility.
- 13 of the 20 popular alternatives earned less than HLN over the past 3 years while swinging more, the weaker corner of the map.
- Over the past 3 years, HLN returned 8.8% a year, less than the S&P 500's 23.7%, with higher volatility (21.5% against 15.2%).

### Has HLN consistently beaten its popular alternatives?

This section compares HLN with the investments people most often weigh against it, checking each one over six periods from one month to three years.

- Four of the 20 popular alternatives, led by CL, WMT and TGT, outperformed HLN in at least 3 of 5 short-term and 1 of 1 long-term timeframes.
- CL, WMT and TGT outperformed HLN in every long-term period and in all but one short-term period, the most consistent record in the group.

| Investment | 1Y return | 3Y return | Periods ahead of HLN | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- |
| HLN: Haleon plc (this page) | +8.8% | +28.9% |  |  | 0.50 |
| [CL](https://easycompare.io/research/cl): Colgate-Palmolive Company | +22.9% | +38.3% | 5/5 short-term, 1/1 long-term | all-weather | 0.65 |
| [WMT](https://easycompare.io/research/wmt): Walmart Inc. | +11.0% | +130% | 4/5 short-term, 1/1 long-term | all-weather | 1.31 |
| [TGT](https://easycompare.io/research/tgt): Target Corporation | +75.1% | +58.0% | 4/5 short-term, 1/1 long-term | all-weather | 0.61 |
| [CVS](https://easycompare.io/research/cvs): CVS Health Corp. | +18.5% | +52.5% | 3/5 short-term, 1/1 long-term | consistent | 0.59 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | +18.9% | +60.0% | 2/5 short-term, 1/1 long-term |  | 0.75 |
| CHD: Church & Dwight Co., Inc. | +21.9% | +21.9% | 5/5 short-term, 0/1 long-term |  | 0.43 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | +30.5% | +19.2% | 4/5 short-term, 0/1 long-term |  | 0.36 |
| ELF: e.l.f. Beauty, Inc. | −10.0% | +12.6% | 4/5 short-term, 0/1 long-term |  | 0.40 |
| KVUE: Kenvue Inc. | +36.7% | +12.0% | 4/5 short-term, 0/1 long-term |  | 0.28 |
| HLF: Herbalife Nutrition Ltd. | +59.7% | −3.0% | 4/5 short-term, 0/1 long-term |  | 0.30 |
| NWL: Newell Brands Inc. | +25.1% | −5.5% | 4/5 short-term, 0/1 long-term |  | 0.28 |
| PRGO: Perrigo Company plc | −18.4% | −35.6% | 4/5 short-term, 0/1 long-term |  | -0.12 |
| COTY: Coty Inc. | −22.0% | −66.1% | 4/5 short-term, 0/1 long-term |  | -0.58 |
| [PG](https://easycompare.io/research/pg): The Procter & Gamble Company | +8.0% | +15.8% | 3/5 short-term, 0/1 long-term |  | 0.36 |
| [EL](https://easycompare.io/research/el): The Estée Lauder Companies Inc. | +5.0% | −18.3% | 3/5 short-term, 0/1 long-term |  | 0.11 |
| PBH: Prestige Consumer Healthcare Inc. | −20.6% | −17.3% | 0/5 short-term, 0/1 long-term |  | -0.08 |
| CLX: The Clorox Company | −23.5% | −20.1% | 0/5 short-term, 0/1 long-term |  | -0.17 |
| NATR: Nature's Sunshine Products, Inc. | −11.1% | −28.6% | 0/5 short-term, 0/1 long-term |  | -0.02 |
| NUS: Nu Skin Enterprises, Inc. | −52.3% | −71.8% | 0/5 short-term, 0/1 long-term |  | -0.53 |
| USNA: USANA Health Sciences, Inc. | −28.8% | −73.7% | 0/5 short-term, 0/1 long-term |  | -0.71 |

### How did HLN do year by year?

This table shows each investment's total return in every full calendar year since 2023, along with where HLN ranked among its popular alternatives each year.

- HLN finished ahead of the S&P 500 in no of its three full calendar years, and behind it in each of the last three.
- Among its popular alternatives, WMT came out ahead of HLN most often, in all three years both traded.
- Ranked against its popular alternatives each year, HLN finished in the top quarter in one of three years and in the bottom quarter in no. In 2025, it ranked 8 of 21.

| Year | HLN | SPY |
| --- | --- | --- |
| 2025 | +7.8% | +17.7% |
| 2024 | +18.1% | +24.9% |
| 2023 | +4.1% | +26.2% |

## Risk and diversification

How HLN has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were HLN's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all five of HLN's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: HLN fell 24.9% from July to September 2022, while the S&P 500 rose 2.7%.
- None of these declines kept HLN below its old high for long; the longest climb back took nine months.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −24.9% | July 18, 2022 | September 2, 2022 | December 6, 2022 | +2.7% | 2022 bear market |
| −23.3% | June 2, 2025 | June 2, 2026 | not yet | +29.6% |  |
| −15.7% | October 1, 2024 | January 14, 2025 | May 2, 2025 | +2.7% |  |
| −13.2% | April 20, 2023 | October 27, 2023 | July 12, 2024 | +0.4% |  |
| −8.2% | February 17, 2023 | March 13, 2023 | March 23, 2023 | −5.4% | 2023 regional bank crisis |

### How did HLN do in stock market crashes?

This section measures how far HLN, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- HLN began trading after the 2008 financial crisis, but 16 of its popular alternatives lived through it. The mildest fall among them was WMT's 26.2%, against 55.2% for the S&P 500.

| Crash | Dates | HLN fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | not trading | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | not trading | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | not trading | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | not trading | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | not trading | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | not trading | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | not trading | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | not trading | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | not trading | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −2.4% | −3.4% |

### How closely does HLN move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- Over the past 3 years, HLN captured 33% of the S&P 500's gains in rising months and 68% of its losses in falling months, with a beta of 0.04. Its share of the market's losses was larger than its share of the gains.
- GSK took just -15% of the S&P 500's losses, against 68% for HLN, while still keeping 42% of its gains.
- Four of the 17 popular alternatives had a higher capture ratio (upside capture divided by downside capture) than HLN's 0.48, led by CL, TGT and CVS.

Measured over the past 3 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| HLN: Haleon plc (this page) | 33.0% | 68.0% | 0.04 |
| [CL](https://easycompare.io/research/cl): Colgate-Palmolive Company | 40.0% | 39.0% | 0.27 |
| [WMT](https://easycompare.io/research/wmt): Walmart Inc. | 80.0% | −3.0% | 0.38 |
| [TGT](https://easycompare.io/research/tgt): Target Corporation | 89.0% | 123% | 0.81 |
| [CVS](https://easycompare.io/research/cvs): CVS Health Corp. | 79.0% | 146% | 0.91 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | 42.0% | −15.0% | -0.01 |
| CHD: Church & Dwight Co., Inc. | 30.0% | 81.0% | 0.42 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | 36.0% | 111% | 0.17 |
| ELF: e.l.f. Beauty, Inc. | 111% | 404% | 3.26 |
| KVUE: Kenvue Inc. | 21.0% | 71.0% | 0.34 |
| HLF: Herbalife Nutrition Ltd. | −25.0% | −33.0% | -0.10 |
| NWL: Newell Brands Inc. | 28.0% | 251% | 0.98 |
| PRGO: Perrigo Company plc | −8.0% | 210% | 1.01 |
| COTY: Coty Inc. | −4.0% | 535% | 1.63 |
| [PG](https://easycompare.io/research/pg): The Procter & Gamble Company | 20.0% | 42.0% | 0.34 |
| [EL](https://easycompare.io/research/el): The Estée Lauder Companies Inc. | 130% | 574% | 1.88 |
| PBH: Prestige Consumer Healthcare Inc. | −4.0% | 76.0% | 0.10 |
| CLX: The Clorox Company | 14.0% | 194% | 0.67 |
| NATR: Nature's Sunshine Products, Inc. | 18.0% | 168% | 0.60 |
| NUS: Nu Skin Enterprises, Inc. | −47.0% | 400% | 0.98 |
| USNA: USANA Health Sciences, Inc. | −78.0% | 277% | 1.16 |

### What diversifies HLN?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in HLN into CLSE would have cut the portfolio's volatility by 21% over the past 3 years and raised its annual return (+4.0% for HLN alone, +9.3% for the mix).
- Among large ETFs, CLSE, IDV and SEIV have moved largely independently of HLN over the past 3 years, with correlations of 0.48 or lower, and each still earned a positive 3-year return.
- Among large stocks, CM, BNY and RY have moved largely independently of HLN over the past 3 years, with correlations of 0.26 or lower, and each still earned a positive 3-year return.

| Investment | Correlation with HLN | 3Y return | Volatility | Sharpe |
| --- | --- | --- | --- | --- |
| CLSE: Convergence Long/Short Equity ETF | -0.14 | +115% | 13.8% | 1.93 |
| IDV: iShares International Select Dividend ETF | 0.48 | +105% | 13.7% | 1.84 |
| SEIV: SEI QiM U.S. Large Cap Value Active ETF | 0.16 | +114% | 14.7% | 1.81 |
| INCM: Franklin Income Focus ETF | 0.38 | +44.3% | 7.2% | 1.74 |
| [CGDV](https://easycompare.io/research/cgdv): Capital Group Dividend Value ETF | 0.21 | +97.2% | 13.7% | 1.73 |
| FMAR: FT Vest U.S. Equity Buffer ETF - March | 0.01 | +54.4% | 8.7% | 1.72 |
| VLUE: iShares MSCI USA Value Factor ETF | 0.01 | +136% | 17.8% | 1.71 |
| AVDV: Avantis International Small Cap Value ETF | 0.38 | +118% | 16.2% | 1.70 |

## Common questions

### What was HLN's worst drawdown?

HLN's deepest decline since it began trading in 2022 was 24.9%, from July to September 2022. It took three months from the low to climb back to its old high. Because HLN launched in July 2022, that record does not include the dot-com bust, the 2008 financial crisis or six other sell-offs.

### What were HLN's best and worst years?

Over three full calendar years, HLN's best year was 2024, when it returned 18.1%. Its worst was 2023, with a return of +4.1%.

### Is there a better investment than HLN?

Among HLN's popular alternatives, CL earned more than HLN with less volatility over the past 3 years: 11.4% a year at 19.8% volatility, against 8.8% a year at 21.5%. Looking beyond its popular alternatives, JNJ (pharmaceuticals) and COST (discount retail) earned more than HLN with less volatility over the past 3 years. JNJ returned 22.7% a year at 18.4% volatility, against 8.8% a year at 21.5%.

### Is HLN more volatile than the S&P 500?

Yes. HLN's volatility over the past 3 years was 21.5%, 1.4 times the S&P 500's 15.2%. Volatility measures how widely returns swing around their average: in roughly two years out of three, HLN's return lands within 21.5% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is HLN's Sharpe ratio?

HLN's Sharpe ratio over the past 3 years was 0.50, against 1.48 for the S&P 500, so HLN earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is HLN with the S&P 500?

Over the past 3 years, HLN's monthly returns had a correlation of 0.02 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are close to unrelated, or move in opposite directions, so it can steady a stock portfolio. In the table, the correlation column measures each option against HLN instead: the lower it is, the more that option would diversify a HLN holding.

### What are the best alternatives to HLN?

Of the 20 popular alternatives we compared, four outperformed HLN in at least 3 of 5 short-term and 1 of 1 long-term timeframes, with dividends reinvested: CL, WMT and TGT.

### Did HLN outperform the S&P 500?

HLN finished ahead of the S&P 500 (SPY) in no of three full calendar years. In 2025, it returned +7.8%, against +17.7% for the index.

### What diversifies HLN?

These had a low correlation with HLN over the past 3 years and still earned a positive 3-year return: among large ETFs, CLSE (correlation -0.14), IDV (correlation 0.48) and SEIV (correlation 0.16); among large stocks, CM (correlation 0.24), BNY (correlation 0.18) and RY (correlation 0.26). A correlation near zero means the two have moved largely independently.

## More research

- [Colgate-Palmolive (CL) Performance, Alternatives and Market Rank](https://easycompare.io/research/cl)
- [Walmart (WMT) Performance, Alternatives and Market Rank](https://easycompare.io/research/wmt)
- [Target (TGT) Performance, Alternatives and Market Rank](https://easycompare.io/research/tgt)
- [CVS Health (CVS) Performance, Alternatives and Market Rank](https://easycompare.io/research/cvs)
- [GSK Performance, Alternatives and Market Rank](https://easycompare.io/research/gsk)
- [Pfizer (PFE) Performance, Alternatives and Market Rank](https://easycompare.io/research/pfe)
- [Procter & Gamble (PG) Performance, Alternatives and Market Rank](https://easycompare.io/research/pg)
- [Estée Lauder Companies (EL) Performance, Alternatives and Market Rank](https://easycompare.io/research/el)
- [Schwab U.S. Dividend Equity ETF (SCHD) Performance, Alternatives and Market Rank](https://easycompare.io/research/schd)
- [NVIDIA (NVDA) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvda)
- [Apple (AAPL) Performance, Alternatives and Market Rank](https://easycompare.io/research/aapl)
- [Alphabet (GOOG) Performance, Alternatives and Market Rank](https://easycompare.io/research/goog)

## Explore further

- Full page with charts: https://easycompare.io/research/hln
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against HLN live: https://betterthanspy.com/?b=HLN&utm_source=easycompare&utm_medium=research